论文部分内容阅读
为了评估高压氧在淋巴瘤化疗中的作用，30例观察组患者采用化疗加高压氧治疗，30例对照组患者单用化疗。比较分析观察组与对照组淋巴瘤的疗效和血象、骨髓象变化及毒副作用的发生率。结果：观察组与对照组比较，瘤块消退速度分别为23．85±3．22cm2／疗程、10．81±2．31cm2／疗程（P＜0．01），诱导CR时间分别为23±8．31天、49±8．81天（P＜0．01），CR率分别为90％、60％（P＜0．05），CR持续时间分别为24．5个月，14．5个月（P＜0．01），中位生存期分别为27个月、16个月（P＜0．01）。10例对照组病人采用高压氧治疗前后自身对照，上述观察指标差异更明显，高压氧治疗可使在化疗中的淋巴瘤患者血象中粒细胞、血小板、骨髓象中粒细胞，巨核细胞，增生度，分裂指数等观察项目下降率明显减低。显然，高压氧可提高淋巴瘤化疗效果，减少复发率，并可能有增强骨髓巨核系，粒系造血功能的作用。
To evaluate the role of hyperbaric oxygen in lymphoma chemotherapy, 30 patients in the observation group received chemotherapy plus hyperbaric oxygen therapy, and 30 patients in the control group received chemotherapy alone. Comparative analysis of the observation group and the control group of lymphoma efficacy and blood, bone marrow changes and the incidence of toxic and side effects. Results: Compared with the control group, the speed of tumor regression was 23.85±3.22cm2/treatment, 10.81±2.31cm2/treatment (P<0.01), and the induction CR time was 23±8. For .31 days and 49±8.81 days (P<0.01), the CR rates were 90% and 60% (P<0.05), and the CR duration was 24.5 months and 14.5, respectively. At month (P<0.01), the median survival time was 27 months and 16 months respectively (P<0.01). In the 10 patients in the control group who were treated with hyperbaric oxygen before and after self-treatment, the above observations showed more obvious differences. The hyperbaric oxygen therapy could be used in the blood of lymphoma patients undergoing chemotherapy for granulocytes, platelets, bone marrow granulocytes, megakaryocytes, and proliferation degree. The drop rate of observation items such as the split index and the other are obviously reduced. Obviously, hyperbaric oxygen can increase the effect of lymphoma chemotherapy, reduce the recurrence rate, and may have the effect of enhancing bone marrow megakaryocyte and hematopoiesis.